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OBJECTIVE—Efforts to map non–major histocompatibility
complex (MHC) genes causing type 1 diabetes in NOD mice
identiﬁed Slc11a1, formerly Nramp1, as the leading candidate
gene in the Idd5.2 region. Slc11a1 is a membrane transporter of
bivalent cations that is expressed in late endosomes and lyso-
somes of macrophages and dendritic cells (DCs). Because DCs
are antigen-presenting cells (APCs) known to be critically in-
volved in the immunopathogenic events leading to type 1 diabe-
tes, we hypothesized that Slc11a1 alters the processing or
presentation of islet-derived antigens to T-cells.
RESEARCH DESIGN AND METHODS—NOD mice having
wild-type (WT) or mutant Slc11a1 molecules and 129 mice having
WT or null Slc11a1 alleles were examined for parameters asso-
ciated with antigen presentation.
RESULTS—We found that Slc11a1 enhanced the presentation of
a diabetes-related T-cell determinant of GAD65, and its function
contributed to the activation of a pathogenic T-cell clone,
BDC2.5. An enhanced generation of interferon (IFN)-–produc-
ing T-cells was also associated with functional Slc11a1. The
alteration of immune responsiveness by Slc11a1 genotype did not
correlate with altered MHC class II expression in DCs; however,
functional Slc11a1 was associated with accelerated phagocytosis
and phagosomal acidiﬁcation in DCs.
CONCLUSIONS—The association of variants encoding Slc11a1
with type 1 diabetes may reﬂect its function in processing and
presentation of islet self-antigens in DCs. Thus, non-MHC genes
could affect the MHC-restricted T-cell response through altered
antigen processing and presentation. Diabetes 58:156–164,
2009
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vidence has been presented supporting Slc11a1
as a non–major histocompatibility complex
(MHC) gene contributing to the development of
spontaneous type 1 diabetes in NOD mice (1–4).
Slc11a1 has been characterized primarily for its ability to
mediate resistance to intracellular pathogens such as
Salmonella and Leishmania via its expression in macro-
phages (5,6). Moreover, recently, Slc11a1 was shown to be
expressed in dendritic cells (7). The protein structural
characteristics of Slc11a1, i.e., 12-transmembrane domains
and a transport motif, indicate a function as an ion channel
and a transporter (5,8). Intracellular staining of Slc11a1 in
macrophages and dendritic cells demonstrated that the
protein is restricted to intravacuolar compartments, espe-
cially late endosomes and lysosomes (7,9,10). A glycine to
aspartic acid substitution at position 169 (G169D) within
the fourth transmembrane domain of Slc11a1 is present in
many mouse strains and reduces Slc11a1 expression on
the phagosomal membrane (11,12). Mouse inbred strains,
such as 129/sv and A/J, resistant to particular intracellular
bacteria/parasite infections, have the wild-type Slc11a1
protein (G169), whereas infection-susceptible strains,
C57BL6/J and BALB/c, express the mutant Slc11a1 protein
(D169) (13). In contrast, for autoimmune disease such as
type 1 diabetes, the resistant allele encodes the mutant
Slc11a1 protein. In humans, polymorphisms correlated
with expression differences have been identiﬁed in the
promoter of Slc11a1 mRNA, which contains several lipo-
polysaccharide (LPS)-related response elements (14,15).
Among several polymorphic alleles of the Slc11a1 gene
that vary in transcription efﬁciency, allele 3, the allele
having the greatest expression, has the highest association
with several autoimmune diseases, including rheumatoid
arthritis, type 1 diabetes, multiple sclerosis, and Crohn’s
disease, whereas the allele having the lowest expression,
allele 2, is commonly associated with susceptibility to
many infectious agents (16).
For a given MHC haplotype, the antigen processing
machineries for class I and II MHC presentation pathways
play a crucial role in selecting which peptides will be
presented efﬁciently, poorly, or not at all on APC. T-cells
recognizing well-presented self-peptides should have been
eliminated in the thymus or tolerized/exhausted in the
periphery, and thus the poorly presented (cryptic) pep-
tides are considered as major players in autoimmunity
(17). In this study, we have tested the hypothesis that
Slc11a1 contributes to type 1 diabetes susceptibility by
altering antigen processing and presentation of certain
poorly presented, diabetes-associated T-cell determinants
in dendritic cells. The expression of Slc11a1 in DCs and its
function on T-cell response were examined in 129/sv mice
with a disrupted Slc11a1 gene (Slc11a1 KO) and two
NOD.B10 congenic mouse strains differing at Slc11a1,
NOD.B10 Idd5.1/5.3 (R193), and NOD.B10Idd5.1/5.3/5.2
(R444). The R193 strain has the NOD-derived functional
Slc11a1 gene and R444 mice have the B10-derived mutant
Slc11a1 gene. We found that R193 DCs could present a
diabetes-associated GAD65 determinant more efﬁciently
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156 DIABETES, VOL. 58, JANUARY 2009than the R444 APC, as well as an islet ligand recognized by
the well-known diabetogenic T-cell clone, BDC2.5. In
addition, Slc11a1 WT mice generated a much stronger Th1
response after immunization with a model antigen, hen
eggwhite lysozyme (HEL), and this Th1 proinﬂammatory
activity of Slc11a1 was similarly observed in 129/Sv mice
when compared with Slc11a1 KO mice. Slc11a1-dependent
MHC class II expression differences on DCs were not
observed; however, evidence supported the ability of
Slc11a1 to accelerate the acidiﬁcation process in DCs.
Thus, altered and/or enhanced antigen processing and
presentation may attribute to the Slc11a1-mediated Th1
response.
RESEARCH DESIGN AND METHODS
Mice. Inbred mouse strains [129S1/SvImJ (129/Sv), NOD/LtJ (NOD), NOR/LtJ
(NOR), NOD.CB17-Prkdc
scid/J (NOD.scid)] were purchased from The Jackson
Laboratory (Bar Harbor, ME). The Slc11a1-null mutant (Slc11a1 KO) was
generated using 129/Sv embryonic stem cells (18), and the KO mice were
maintained at the animal facility of Torrey Pines Institute for Molecular
Studies (TPIMS). The NOD.B10 congenic strains NOD.B10 Idd5.1/5.3 (R193)
and NOD.B10 Idd5.1/5.3/5.2 (R444) were developed as described in Hunter et
al. (4) and were obtained from Taconic (Hudson, NY) and maintained as
inbred strains at TPIMS. BDC2.5 TcR transgenic NOD mice were maintained
at TPIMS by backcrossing with NOD mice. Experimental protocols were
conducted with approvals from the TPIMS Ethical Review Committee.
APC preparation. To prepare bone marrow (BM)-derived DCs, bone marrow
was collected from femurs and tibias, and red blood cells in the marrow were
lysed with red blood cell lysing buffer (Sigma). Fresh granulocyte-macrophage
colony-stimulating factor (GM-CSF) (100 units/ml) was added every other
day to stimulate the bone marrow cells (10
6 cells/well) adherent to a 24-well
plate. The proliferating immature DCs were harvested by gentle dislodging on
day 6 and plated in a 60-mm
2 culture Petri dish (10
7 cells/ml) in complete
medium with GM-CSF. The mature DCs present after 24-h incubation become
nonadherent, after which they are collected for further studies. Splenic APCs
were enriched after plastic adherence. Brieﬂy, red blood cell–lysed spleno-
cytes (10
7/ml) are allowed to adhere to plastic in serum-free RPMI media at
37°C for 60–90 min, followed by repeated gentle washes with medium to
remove nonadherent splenocytes until the plate bottom becomes transparent.
Then, complete 10% FCS medium is added to continue the incubation
overnight to release the adherent DCs. Splenic CD11c
 DCs were isolated
using anti–CD11c-coated magnetic microbeads (Miltenyi Biotec, Auburn, CA)
according to the product instructions.
Antigens, peptide synthesis, and islet isolation. GAD65 peptides p206–
220, p217–236, p246–266, p286–300, p524–538, p530–543, and p524–543 were
synthesized at the peptide synthesis laboratory of the University of California,
Los Angeles, on an Advanced Chemtech 395 Synthesizer using F-moc chem-
istry and puriﬁed by high-performance liquid chromatography to 90% purity.
The Ig-GAD1 and Ig-HEL chimeric molecules were constructed by Dr.
Zaghouani by inserting the GAD65 p524–543 or HEL p11–25 nucleotide
sequences into the variable region of the H-chain of Ig molecules (19).
Baculovirus-expressing recombinant GAD65 (rGAD65) was obtained from Dr.
Nora Sarvetnick at the Scripps Research Institute (La Jolla, CA). Isolation of
islets was performed as follows: 3 ml 0.46 mg/ml collagenase dissolved in
Hanks’ balanced salt solution buffer was injected into pancreatic glands
through the bile duct, followed by digestion in a 37°C water bath for 18–20
min and disruption by vigorous shaking at the end of incubation. The digestion
was terminated by washing once with ice-cold Hanks’ balanced salt solution
buffer, and the debris was resuspended in 10 ml of 10% fetal calf serum (FCS)
RPMI medium. Single islets were picked under a dissection microscope. An
average of 100–250 islets per adult NOD.scid pancreas can be expected.
T-cell proliferation and activation assay. T-cell lines speciﬁc for GAD65
peptides, p530–543 or p524–543, were generated by immunizing NOD mice
with 100 g of the peptides emulsiﬁed in complete Freund’s adjuvant (Difco).
Draining lymph nodes and spleens were collected 9–12 days later and
expanded in vitro with 10 g/ml of the respective peptide for 3 days followed
by resting in 10 units/ml of rIL-2 in complete RPMI media, containing 10% FCS,
penicillin (100 units/ml) and streptomycin (100 g/ml), 2 mmol/l L-glutamine,
10 mmol/l HEPES buffer, and 0.1 mmol/l of minimal essential medium with
nonessential amino acids (Gibco, Invitrogen, San Diego, CA). The lines were
further expanded once with p524–543, using irradiated NOD splenocytes as
APCs, and rested for at least 7 days in 10 units/ml of rIL-2 before testing for
an antigen-speciﬁc T-cell response. For T-cell proliferation or activation
assays, 1–2  10
5 peptide-speciﬁc T-cells or puriﬁed CD4
 BDC2.5 T-cells
(isolated with anti–CD4-coated magnetic microbeads; Miltenyi) were mixed
with various antigens or the pancreatic islets and APCs or puriﬁed DCs. After
3 days of culture,
3H-thymidine (International Chemical and Nuclear, Irvine,
CA) was added for another 18 h of culture. Cells were harvested with a Micro
Cell Harvester (Skatron Instruments, Sterling, VA), and incorporation of
3H-thymidine was measured on a Wallac MicroBeta Trilux counter (Perkin
Elmer, Boston, MA). In some experiments, culture supernatants were col-
lected at 72 h for measuring interferon (IFN)- concentrations using a
commercial enzyme-linked immunosorbent assay (ELISA) kit (BD Bioscience,
San Diego, CA).
ELISPOT. The number of HEL-speciﬁc, IFN-–secreting T-cells was evalu-
ated in R193 and R444 mice immunized with HEL, using an enzyme-linked
immunosorbent spot (ELISPOT) assay (BD Biosciences). Brieﬂy, ELISPOT
plates (MAHA S45 10, Millipore) were ﬁrst coated overnight at 4°C with
anti–IFN- mAb (5 g/ml; BD Biosciences) and blocked with 1% BSA
(Fraction V; Sigma Aldrich) in PBS. HEL-primed splenocytes (10 days after
immunization) were added at 5  10
5/well for 48 h at 37°C in the presence of
100 or 500 g/ml of HEL, or 5 g/ml of Concanavalin A as a positive control,
or media only. IFN- secretion was detected with a second biotinylated
anti–IFN- mAb (2 g/ml; BD Biosciences). Spots were developed using
streptavidin–horseradish peroxidase and 3-amino-9-ethyl-carbazole (AEC)
substrate.
Western blotting for Slc11a1 in macrophages and DCs. Macrophages
were collected from the peritoneal cavity 3 days after injection of 3 ml of 3%
thioglycollate media. BM-derived DCs were stimulated with 2 g/ml LPS for
24 h for further maturation. A total of 1–2  10
7 cells were lysed in 100–200
l cell-lysing buffer (containing 20 mmol/l Tris-HCl, 5 mmol/l EDTA, 1% NP-40,
1 mmol/l NaVO4, 1% SDS, and 10 g/ml aprotinin/leupeptin) for 15 min on ice,
followed by centrifugation at 15,000 rpm for 20 min at 4°C. Cell lysates were
collected for SDS-PAGE. Samples were denatured at 37°C for 30 min using a
5 sample buffer that contains 10% SDS, 10 mmol/l -mercaptoethanol, 20%
glycerol, 0.2 mol/l Tril-HCl (pH 6.8), and 0.05% bromophenol blue. SDS-PAGE–
separated protein samples were electro-transferred to a polyvinyl derivative
membrane (Amersham Biosciences, Piscataway, NJ) using a semi-dry trans-
blot (Bio-Rad Laboratories, Hercules, CA). The membrane was immuno-
blotted with the anti-Slc11a1 antibody (1:1,000 dilution) or a control anti-ERK
antibody (1:500) (Cell Signaling Technology, Danvers, MA), followed by
horseradish peroxidase–conjugated secondary antibodies and visualized with
an enhanced chemiluminescence (ECL) detection system (Amersham).
FACS and intracellular ﬂow cytometry. Antibodies speciﬁc for MHC class
II I-A
g7 (AMS-32.1), I-A
b (AF6–120.1), CD80 (16–10A1), CD11c (HL3), and
ﬂuorescence-labeled anti-Ig antibodies were purchased from BD BioScience
(San Diego, CA). Slc11a1-speciﬁc polyclonal antibody was produced in rabbits
after immunization with a NH2-terminal peptide from the mouse Slc11a1
molecule as described (12). For intracellular staining of Slc11a1 protein,
splenic plastic adherent APCs were ﬁxed with 3.7% paraformaldehyde for 10
min, followed by membrane perforation with 0.5% Saponin dissolved in 1%
BSA/PBS for 10 min on ice. The perforated cells were then blocked with 1
g/ml anti-CD16 (FcR) before staining with the Slc11a1-speciﬁc antibody
(1:500 dilution in 0.1% Saponin). After three washes with 0.1% Saponin, cells
were further incubated with a second anti-rabbit Ig labeled with ﬂuorescein
(BD BioScience) or the anti-CD11c antibody, and the staining was detected
using FACSCalibur (BD BioScience, San Jose, CA).
Phagocytosis and phagosomal acidiﬁcation. A modiﬁed protocol to mea-
sure the rates of phagocytosis and phagosomal acidiﬁcation using ﬂow
cytometry was established after a described protocol by Savina et al. (20), in
which DC phagocytosis was induced using iron-coated microbeads with a
diameter of 40–50 nm (Miltenyi) that were preconjugated with pH-sensitive
dyes (FITC) and pH-insensitive dyes (PE). The conjugation was performed by
incubation of 250 l protein-G microbeads (Miltenyi) with 20 g of each FITC-
and PE-labeled rat Igs for 30 min on ice, followed by puriﬁcation with a
magnetic cell separation (MACS) MS column (Miltenyi) to remove excess
antibodies. The FITC/PE-labeled microbeads were eluted in 250 l MACS
buffer and used to pulse DCs. At different time points, the ﬂuorescence
intensity of FITC and PE of the pulsed DCs was monitored by FACS. Because
PE is relatively stable to pH change or phagosomal degradation, the accumu-
lation of PE on DCs reﬂects the rate of phagocytosis. The pH-sensitive FITC
dye is an indicator of phagosomal degradation, and a change of the FITC/PE
ratio will reﬂect the relative pH values or the rate of acidiﬁcation process
within the DC phagosomes.
RESULTS
Slc11a1 enhances processing and presentation of a
diabetogenic T-cell determinant, p524–543, of GAD65.
Spontaneous autoreactive T-cell responses to several
GAD65 peptides correlate with the development of diabe-
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speciﬁc T-cell responses in two NOD.B10/Idd5 congenic
strains, R193 and R444, which carry functional versus
nonfunctional mutant Slc11a1 alleles, respectively. Only
the R193 strain showed a proliferative response to several
known GAD65 T-cell determinants: p206–220, p524–538,
p530–543, and p524–543 (Fig. 1A). In contrast, splenocytes
collected from the Slc11a1-nonfunctional R444 mice
showed no reactivity to any of the tested peptides, indi-
cating a lack of peripheral activation or expansion of
GAD65-reactive T-cells in the R444 strain. To examine
whether Slc11a1 could affect the processing and presen-
tation of GAD65, we used an Ig-chimeric antigen that
includes one of the dominant determinants of GAD65,
p524–543, in the variable region of the Ig H-chain (19); In
Fig. 1B, presentation of the p524–543 determinant after
processing of the Ig-chimeric antigen by splenic adherent
APC was detected using a p530–543–speciﬁc T-cell line; it
was found that only the R193 APCs were efﬁcient in
processing the chimeric molecule; a control chimeric mole-
cule, Ig-HEL, as well as the R444 APC proved to be inactive
for stimulating the T-cells. Similar results were obtained
when recombinant GAD65 protein was used as antigen, in
that R193 APCs were more efﬁcient in activating the p524–
543–speciﬁc T-cells to secrete IFN- (Fig. 1C). These data are
consistent with a conclusion that Slc11a1-expressing APCs
are more efﬁcient in processing and presenting this diabetes-
associated GAD65 determinant.
Activation of a highly pathogenic diabetes-associated
T-cell clone, BDC2.5, requires Slc11a1 expression in
dendritic cells. The BDC2.5 T-cell clone is diabetogenic
in NOD mice (23,24) and strongly reactive to a membrane
protein of 50–85 KDa expressed in normal islet -cells
(25). To examine whether Slc11a1 could affect the pro-
cessing and presentation of the ligand to stimulate this
islet-inﬁltrating T-cell clone, we ﬁrst performed an in vitro
T-cell proliferation assay, in which CD4
 BDC2.5 T-cells
were cultured with freshly isolated splenic APCs in the
presence of different numbers of the pancreatic islets or
media. We were able to stimulate BDC2.5 T-cells using
only two islets per well (Fig. 2A), whereas BDC2.5 cells
were unresponsive in the absence of the islets despite the
addition of LPS-activated splenic APCs (data not shown),
suggesting that a speciﬁc high-afﬁnity antigen presented in
the islets was necessary to activate naive BDC2.5 T-cells.
At 20 islets per well, a stimulation index of 20 could be
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FIG. 1. Slc11a1 enhanced processing and presentation of GAD65 T-cell determinants. A: Spontaneous T-cell response to GAD65 in R193 (Slc11a1
WT) and R444 (Slc11a1 mutant) Idd5 congenic mice. Spleen cells were prepared from 16-week-old female R193 or R444 mice and cultured with
synthetic peptides derived from the mouse GAD65 molecule: p206  206–220, p217  217–236, p246  246–266, p286  286–300, p524  524–538,
p530  p530–543, and p543  524–543. B: An Ig-GAD chimeric molecule was used as the recall antigen for T-cells speciﬁc for GAD65 p530–543
peptide. C: Recombinant GAD65 (rGAD65) was used to stimulate a p524–543–speciﬁc T-cell line. Positive controls (with 5 g/ml of p524–543
peptide): R193.APC  2.80  0.06, R444.APC  2.95  0.12. Background odds density (OD) values were subtracted from the data shown:
R193.APC  0.19  0.004, R444.APC  0.20  0.003. Each experiment is representative of two experiments performed.
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the same conditions, the R444 APCs were not as efﬁcient
in processing the islets, resulting in a lesser proliferation
of BDC2.5 T-cells with a stimulation index of 5 (Fig. 2A).
Additionally, we observed that islets isolated from a
diabetes-resistant, NOD-congenic mouse strain, NOR,
were essentially equivalent to the islets from NOD mice in
stimulating BDC2.5 T-cells (Fig. 2A), indicating that the
ligand of BDC2.5 cells is also presented in the NOR islets.
Finally, this Slc11a1-dependent processing was sensitive
to chloroquine treatment, since the activation of BDC2.5
T-cells by islets was reduced by addition of 100 mol/l
chloroquine in the culture (Fig. 2B). Therefore, insufﬁcient
processing and presentation of some T-cell determinants
such as the BDC2.5 ligand correlated with the diabetes
resistance observed in the R444 and the NOR strains.
Slc11a1 enhanced Th1-mediated response to HEL
immunization. Slc11a1 is proinﬂammatory, but it is not
clear whether Slc11a1 directly affects the production of
inﬂammatory cytokines by DCs and macrophages or
through indirect activation of T-cells. Nevertheless, en-
hanced Th1 bias would accelerate autoimmune destruc-
tion in the pancreas. We therefore examined the immune
response and the cytokine proﬁles in the congenic NOD
strains, R193 and R444, after HEL immunization. The
Slc11a1-nonfunctional R444 mice mounted a similar prolifer-
ative response to HEL compared with R193 mice, as assessed
using their HEL-primed splenocytes (Fig. 3A); however, there
was a dramatic increase in IFN- production by the R193
lymphocytes, over two to threefold more than that produced
by the R444 cells, as detected by ELISA (Fig. 3B) as well as
by ELISPOT assays (Fig. 3C). Similar ELISPOT results were
observed when Slc11a1 WT vs. KO mice were immunized
with HEL (Fig. 3D), conﬁrming a strong bias toward Th1
response in the presence of Slc11a1.
Slc11a1 does not affect the expression levels of MHC
class II and costimulatory molecules. It has been
reported that Slc11a1 function correlates with IFN-–
induced MHC class II expression on BM-derived macro-
phage cell lines (26). We therefore examined MHC class II
expression on freshly isolated, as well as LPS-stimulated
splenic, DCs. CD11c was used to identify or isolate the
myeloid DC population. Splenic DCs were isolated from
R193 versus R444, or WT versus KO splenocytes by
anti–CD11c-coated magnetic microbeads, followed by
staining using ﬂuorescent anti–I-A
b, anti–I-A
g7, anti-CD80,
or anti-CD11c antibodies. We observed that in three inde-
pendent experiments, DCs from both the NOD congenic
pair (Fig. 4A) and the WT versus KO mice (Fig. 4B)
expressed comparable levels of MHC class II (I-A
g7 or I-A
b,
respectively) and CD80 (B7.1) molecules; and this observa-
tion remained unchanged when LPS-activated CD11c
 DCs
(Fig. 4A, lower panel) were examined. In addition, knockout
of Slc11a1 did not change the percentage of the
CD11c
CD8
 DC subset within the isolated splenic CD11c

DC population, as shown in Fig. 4C. Therefore, the pro-Th1
function of Slc11a1 should not be attributable to enhanced
expression of the MHC class II or B7.1 costimulatory mole-
cules on APCs. An alternate hypothesis is that the observed
pro-Th1 function of Slc11a1 could be an indirect result of
differential activation of T-cells with higher afﬁnity due to
altered antigen processing in Slc11a1-expressing APCs.
Slc11a1 enhances phagocytosis and acidiﬁcation. To
compare the rates of phagocytosis and phagosomal acidi-
ﬁcation between Slc11a1 functional DCs (R193 and
Slc11a1 WT) and nonfunctional DCs (R444 and Slc11a1
KO), mature DCs generated separately from the bone
marrows of the R193, R444, WT, and KO mice were
incubated with the preformed FITC/PE-microbeads (see
RESEARCH DESIGN AND METHODS) at 37°C for various periods,
followed by FACS analysis to monitor the DC-bound FITC
and PE dyes. Within certain periods (5–7 h in our experi-
ments), the ﬂuorescence intensity is positively correlated
with incubation times. In four separate experiments, we
repeatedly observed a faster accumulation of the ﬂuores-
cent dyes in the R193 or WT DCs, in comparison with DCs
from the R444 or KO mice (Fig. 5A), suggesting that
Slc11a1 can enhance the phagocytosis of the FITC/PE-
0
5
10
15
20
25
30
20 islets 2 islets
B
D
C
2
.
5
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
(
S
I
)
NOD islets
20 islets 2 islets
NOR islets
R193 DC
R444 DC
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Islets Islets / Chlq.
B
D
C
2
.
5
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
(
S
I
)
FIG. 2. Pancreatic islet antigens are processed more efﬁciently by the R193 than by the R444 DCs. A: BDC2.5 T-cells were isolated from transgenic
mice with anti-CD4 MACS beads; DCs were enriched from R193 or R444 splenocytes by plastic adherence; islets were handpicked from digested
NOD, NOD.scid, or NOR pancreas. For proliferation assays, BDC2.5 (100,000/well) were cultured with DCs (20,000/well) and 20 or 2 islets for 72 h
followed by an additional 18 h with
3H-thymidine. Negative controls had no islets: R193  1,460 cpm, R444  4,675 cpm. Each number represents
the mean of triplicate wells. B: The ratio of BDC2.5 T-cells: DCs remained at 5:1. The difference in this experiment was that DCs were puriﬁed
using anti-CD11c microbeads, and 100 mol/l chloroquine was added for inhibition of processing. Background: R193  2,325 cpm, R444  3,390
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sensitive dye that degrades in an acidic environment, a
drop in the FITC/PE ratio would indicate a more acidic
environment. Thus, this ratio can be used to monitor pH
change or the acidiﬁcation process in phagosomes. Figure
5B demonstrates that this ratio decreased more rapidly in
the R193 or WT DCs, suggesting that Slc11a1 mediates an
enhanced acidiﬁcation process in DCs after taking up the
FITC/PE-microbeads. In four separate experiments using
both the R193 and R444 congenic pair and the Slc11a1 WT
and KO mice in parallel, Slc11a1 functional DCs persis-
tently showed a lower FITC/PE ratio and a faster drop of
this ratio, although the differences were relatively small
except for one of the experiments. Similar results were
also observed when splenic DCs, collected by plastic
adherence, were used. In addition, the NOD background of
the R193 and R444 mice clearly contributes to a much
more vigorous phagocytic activity in comparison with the
129/sv background of the WT and KO mice (Fig. 5A).
Slc11a1 is expressed in subsets of activated DCs.
Western blotting of Slc11a1 is problematic owing to its
highly hydrophobic features (12 transmembrane do-
mains). However, using an antibody speciﬁc for the NH2-
terminal region of the Slc11a1 molecule, we were able to
detect a band in WT but absent from KO peritoneal
macrophages (data not shown), which conﬁrmed a previ-
ous report by Vidal et al. (12). Importantly, we demon-
strate, for the ﬁrst time, a similar band (100 kDa) in WT
BM-derived DC samples, and the density of this band was
enhanced after LPS stimulation (Fig. 6A). The fuzziness of
the band can be ascribed to the heavy glycosylation and/or
phosphorylation of the Slc11a1 protein (12). To examine
Slc11a1 protein expression in splenic DCs, we established
a ﬂow cytometry protocol to stain intracellular Slc11a1
molecules. Figure 6B shows that despite a high back-
ground of the anti-Slc11a1 antibody, a majority of the
LPS-activated, CD11c
 WT, but not KO, splenic DCs
express Slc11a1. Therefore, Slc11a1 can be upregulated in
certain subsets of splenic DCs after stimulation with LPS.
DISCUSSION
Slc11a1 expressed in DCs. In this study, we demon-
strated that both BM-derived DCs and splenic CD11c
 DCs
express Slc11a1, conﬁrming a recent report that Slc11a1 is
expressed in dendritic cells (7). However, by comparing
Slc11a1 WT and KO DCs on the 129 genetic background as
well as DCs from congenic NOD strains expressing WT
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conﬁrm the difference in MHC class II expression previ-
ously reported using BM-derived DCs from Slc11a1 con-
genic mice on the B10 genetic background (7). Instead we
saw equivalent class II expression on freshly isolated as
well as LPS-stimulated splenic DCs (Fig. 4). We also
examined unstimulated CD8
 or CD8
 CD11c
 DC sub-
sets, and similarly, we found no difference between the
Slc11a1 WT and KO in their MHC class II expression level.
In addition to the genetic background differences present
in the two studies, it is possible that the cell types
examined (BM-derived DCs in the case of Stober et al. and
splenic DCs in our study) could account for the discrepant
observations. Because different DC subsets or maturation
stages vary in their MHC class II expression level, the
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rate of BM-derived DCs in vitro, whereas splenic DC
subsets have differentiated entirely in vivo.
Selectively enhanced antigen presentation by
Slc11a1. Because we lacked evidence that the level of
MHC class II molecules on the surface of DCs was altered
by the status of Slc11a1, we hypothesized that Slc11a1
alters antigen processing. We presented evidence that
Slc11a1 enhances the rates of phagocytosis and phagoso-
mal acidiﬁcation in DCs (Fig. 5) and enhances the process-
ing and presentation of certain T-cell determinants (Figs. 1
and 2); therefore, we propose that Slc11a1 alters antigen
presentation by altering the processing machinery, rather
than increasing the expression of MHC class II molecules
on DCs. In other ongoing studies of the processing and
presentation of HEL protein, we have observed that for
particular HEL-speciﬁc T-cell clones, APCs lacking
Slc11a1 are twofold more efﬁcient than the APCs from WT
mice in processing HEL and activating such clones
(Y.D.D., I.G.M., E.E.S., and C.R. Gabaglia, unpublished
data). Thus, the enhanced antigen presentation by Slc11a1
in the current study is likely selective, rather than owing
to nonspeciﬁc enhancement of any available T-cell
determinants.
Proinﬂammatory activity of Slc11a1. We observed a
strong induction of IFN-–secreting Th1 cells after HEL
immunization (Fig. 3). This pro-Th1 activity of Slc11a1
does not necessary require a strong adjuvant such as
complete Freund’s adjuvant, since a similar increase of
IFN-–producing cells was also observed in R193 mice
after immunization with HEL emulsiﬁed in incomplete
Freund’s adjuvant (data not shown). Stober et al. (7)
reported that there was a signiﬁcant increase of the ratio
of IL-10/IL-12 mRNA in mutant DCs, but the difference was
mainly obvious in unstimulated DCs. Again, these DCs
were produced in vitro from bone marrow after stimula-
tion with GM-CSF and IL-4 for over 10–15 days. It remains
to be addressed whether Slc11a1 could exhibit a similar
effect on the ratio of IL-10/IL-12 production in freshly
isolated peripheral DCs. Alternatively, as proposed in this
study, Slc11a1 may promote a proinﬂammatory state and a
response with a Th1 bias by altering antigen processing
and presentation, e.g., by inducing T-cell clones with
higher afﬁnity, or by reducing the speciﬁc regulatory T-cell
population. Future experiments will address whether such
proinﬂammatory activity of Slc11a1 is seen for antigens
other than GAD65 and HEL. Such altered processing may
favor enhanced generation of usually cryptic determinants
from the target antigens, or eliminate certain determinants
related to regulatory function, or create modiﬁed determi-
nants of the antigens with higher afﬁnity.
Enhanced intracellular vesicle fusion and/or acidiﬁ-
cation by Slc11a1. The intracellular interaction of
Slc11a1 with antigens or pathogens remains unclear. By
fusing with intracellular vesicles and/or recruiting newly
synthesized molecules, primary endocytic vesicles or
phagosomes enter a gradual maturation process, which
includes early endosomes, later endosomes, and lyso-
somes. During this maturation process, the hydrolytic
activity of the endocytic vesicles increases gradually as the
luminal pH value decreases from pH 6.3–6.8 in early
endosomes to pH 4.5–5.5 in lysosomes; this pH drop might
vary in different cell types and/or depend on their activa-
tion status. It has been suggested that Slc11a1 functions as
a membrane transporter of divalent cations (27), but its
mechanism of mediating natural resistance to bacterial
and parasitic infections remains unclear. Previous studies
on the innate response of macrophages during intracellu-
lar bacterial infection suggested that Slc11a1-mediated
deprivation of divalent cations might change the phagoso-
mal microenvironment that impairs the pathogenesis of
intracellular pathogens (27). Alternatively, the transporter
activity of Slc11a1 might accelerate the acidiﬁcation pro-
cess by either enhancing the fusion of phagosomes with
late endosomes/lysosomes, or by increasing V-ATPase
activity and proton accumulation in the phagosomes
(28,29). Our data from measuring intracellular pH values in
DCs (Fig. 5) are consistent with previous ﬁndings that
Slc11a1 contributes to enhanced phagosomal acidiﬁcation
in macrophages (28), although the differences we ob-
served between DCs from the wild-type versus the mutant
strains were less robust, which may be due to a less
sensitive method (ﬂow cytometry) that we used. If we
could monitor the FITC/PE ratio within the intracellular
later endosomes or lysosomes where the Slc11a1 mole-
cules are expressed, we might see a stronger difference.
We propose that in the presence of Slc11a1 protein,
altered antigen transport or an increased intravascular
acidic environment might expose the antigens to certain
hydrolytic enzymes, such as aspartic and cysteine pepti-
dases and amino- or carboxy-peptidases, or to an overall
stronger hydrolytic activity, leading to differential presen-
tation of T-cell epitopes on MHC molecules. It can be
expected that such Slc11a1-mediated changes in antigen
processing within the vesicular system could have general
effects in autoimmune as well as in infectious systems.
Altered antigen processing and presentation in type
1 diabetes. APCs have long been considered as contrib-
uting to diabetes susceptibility (30–32) owing to their
exclusive expression of MHC class II, the major genetic
factor underlying type 1 diabetes. Some efforts have also
been made to identify diabetes-associated genes that are
involved in antigen-processing pathways (33–37), but most
of these results have been either contradictory or incon-
clusive. This is indicative of the difﬁculty in using genetic
tools to link individual genes to a particular phenotype in
such a complicated multigene-involved autoimmune dis-
ease, although it has been suggested that diabetogenic
genes affecting pathogenesis inﬂuenced by APCs are inde-
pendent from those genes regulating T-cell activity (38). A
few genes involved in class II processing pathways have
been studied for their effects on diabetes in NOD mice
using gene knockout NOD mice, instead of natural mu-
tants. Cathepsin (Cat) L–deﬁcient NOD mice failed to
develop insulitis as well as diabetes (39). The authors
found decreases in the percentage of total CD4 T-cells as
well as of the diabetogenic BDC2.5 T-cell, but a relative
increase of CD4
CD25
 regulatory T-cells. Loss of the
invariant (Ii) chain, the chaperone for the class II process-
ing pathway, also protected NOD mice from diabetes (40).
Similarly, decreased CD4 numbers were found in both the
thymus and the periphery, but the percentage of
CD4
CD25
 regulatory T-cells remained constant, indicat-
ing that these regulatory cells may mature in the thymus
and/or differentiate in the periphery through an Ii-indepen-
dent pathway. The decreased ratio of pathogenic versus
regulatory T-cells could be an explanation in the above
two studies, but more likely, the altered antigen process-
ing of self-antigens in the thymus versus the periphery may
interfere with the speciﬁc association of I-A
g7 with diabe-
tes in NOD mice—an essential pathway in which non-MHC
genes contribute to MHC-associated autoimmune disease.
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would be expected after such drastic alterations of the
antigen-processing machinery.
An interesting question for autoimmunity in general is
why defective processing machinery should affect a T-
cell–dominant autoimmune response. A short answer is
that some pathogenic T-cell determinants require a partic-
ular enzymatic activity within the APCs processing ma-
chinery, which is also able to prevent or reduce the
generation of regulatory determinants for presentation to
MHC class II–restricted T-cells. Our early idea of MHC-
guided processing as a major pathway in antigen presen-
tation (42) was strongly supported by data showing that
very long lysozyme peptides of approximately 70 amino
acids could be detected in peptide elution experiments
(41). Subsequently, the MHC-bound peptide is trimmed at
both ends (43) to yield the typical short 13–25 residue
peptides still bound to class II MHC (44,45). Recently, we
demonstrated that trimming of the ﬂanking residues of a
diabetes-associated GAD65 peptide could affect the selec-
tion of individual T-cell clones for activation (46), and
importantly, such trimming events varied between diabe-
tes-susceptible and -resistant strains, with the susceptible
strain exhibiting an enhanced selection of diabetogenic
T-cells. How this selection process, catalyzed by MHC-
guided trimming, is associated with disease development,
and whether Slc11a1 is involved in this process remains to
be learned. Further studies of this heterogeneous epitope-
speciﬁc repertoire and its diverse functional phenotypes
are indicated.
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